Mounjaro vs Retatrutide in Special Populations: A Head-to-Head Comparison

What Are Mounjaro and Retatrutide, and How Do They Differ?

Mounjaro (tirzepatide) targets two receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Retatrutide adds a third mechanism by also agonizing the glucagon receptor. That third target accelerates fatty-acid oxidation in the liver and brown adipose tissue, which may explain the additional weight reduction seen in early trials.

Mechanism Side by Side

Tirzepatide was designed as a "twincretin", one molecule that simultaneously activates GIP-R and GLP-1R. The GIP component amplifies insulin secretion and may blunt nausea relative to pure GLP-1 agonists, while the GLP-1 component suppresses appetite and slows gastric emptying. The FDA approved tirzepatide for type 2 diabetes in May 2022 and for chronic weight management in November 2023 under the brand Zepbound. [1]

Retatrutide is a "triagonist." Glucagon receptor activation raises energy expenditure by stimulating thermogenesis and hepatic fat oxidation, effects that GLP-1 and GIP agonism alone do not produce as strongly. Preclinical data show glucagon agonism can increase resting metabolic rate by 15 to 25% in rodent models, though human translation is still being measured in ongoing phase 3 work. [2]

What the Phase 2 Retatrutide Trial Actually Showed

The Jastreboff et al. 2023 NEJM phase 2 trial (N=338) tested retatrutide 1 mg, 4 mg, 8 mg, and 12 mg against placebo in adults with BMI of 27 to 50. At 24 weeks, the 12 mg arm produced 17.5% mean body-weight reduction. By 48 weeks, that figure reached 24.2%, the highest weight-loss signal recorded for any GLP-1 class agent in a controlled trial at that duration. [2] Adverse events were mostly gastrointestinal (nausea 45%, vomiting 25% in the 12 mg cohort), consistent with GLP-1 class effects.

Tirzepatide's landmark SURMOUNT-1 trial (N=2,539) showed 20.9% mean weight loss at 72 weeks with 15 mg and 22.5% in the per-protocol population. [3] The 48-week weight loss in SURMOUNT-1 with 15 mg was approximately 18 to 19%, somewhat below retatrutide's 24.2% at the same timepoint, though cross-trial comparisons must be made cautiously given different populations and designs.

Head-to-Head in Type 2 Diabetes

For people with type 2 diabetes, tirzepatide holds a clear regulatory advantage. Retatrutide is being studied in the TRIUMPH-1 and TRIUMPH-2 phase 3 programs in T2D, but results are not yet published as of mid-2025.

Glycemic Control with Tirzepatide

SURPASS-2 (N=1,879, 40 weeks) compared tirzepatide 5 mg, 10 mg, and 15 mg against semaglutide 1 mg in adults with T2D and A1c 7.5 to 11%. Tirzepatide 15 mg reduced A1c by 2.46 percentage points versus 1.86 for semaglutide 1 mg (P<0.001). [4] Tirzepatide 15 mg also produced 12.4% body-weight reduction versus 6.2% for semaglutide.

Across the full SURPASS program (SURPASS-1 through SURPASS-5), tirzepatide consistently outperformed insulin degludec, insulin glargine, and semaglutide 1 mg on both A1c and weight endpoints. Up to 92% of participants reached A1c below 7.0% with the 15 mg dose. [5]

What Retatrutide Adds in T2D (Phase 2 Signal)

The phase 2 T2D cohort within the retatrutide program showed A1c reductions of up to 2.02% with the 12 mg dose at 24 weeks in a smaller exploratory arm. The glucagon component raises a theoretical concern: glucagon receptor agonism can increase hepatic glucose output. In practice, the GLP-1 and GIP components appear to dominate, keeping fasting glucose in check, but the TRIUMPH phase 3 data are needed before clinicians can act on this. Prescribing retatrutide for T2D outside a clinical trial is not possible in 2025.

Head-to-Head in Obesity Without Diabetes

This is where the comparison becomes most clinically consequential, because both agents are being developed (or have already been approved) specifically for obesity management.

Tirzepatide's SURMOUNT Data

SURMOUNT-1 enrolled adults with BMI at or above 30, or BMI of 27 with at least one weight-related comorbidity, without diabetes. At 72 weeks, 15 mg tirzepatide produced a 20.9% mean reduction in body weight, and 63% of participants lost at least 20% of body weight. [3] The number needed to treat to achieve 15% body-weight loss was approximately 2 against placebo.

SURMOUNT-2 (N=938) focused on adults with T2D and obesity and showed 15.7% weight reduction at 72 weeks with tirzepatide 15 mg, lower than the non-diabetic cohort, which mirrors findings across the GLP-1 class. [6]

Retatrutide's Phase 2 Obesity Signal

In the Jastreboff 2023 phase 2, participants with obesity (no diabetes) receiving retatrutide 12 mg lost 24.2% of body weight at 48 weeks. [2] Extrapolating that trajectory to 72 weeks is speculative, but if the curve follows tirzepatide's pattern, the final weight-loss percentage may approach 28 to 30%. Phase 3 (TRIUMPH-3, enrolled but not yet reported) will confirm or contradict that estimate.

At 48 weeks in SURMOUNT-1, tirzepatide 15 mg produced approximately 18 to 19% weight reduction, making the cross-trial difference roughly 5 to 6 percentage points in favor of retatrutide at the same duration. That gap, if confirmed in phase 3, would be clinically meaningful.

Clinical Decision Framework: Mounjaro vs. Retatrutide in Obesity (2025)

| Factor | Choose Mounjaro (Tirzepatide) | Consider Retatrutide | |---|---|---| | Regulatory status needed | FDA-approved; use now | Enroll in TRIUMPH trial | | Weight-loss target above 20% | Achievable in ~63% at 72 wk | May exceed 20% more often (phase 2 signal) | | T2D comorbidity | Approved, extensive safety data | Phase 3 ongoing; not prescribable | | CKD stage 3-4 | No dose adjustment required | Data pending | | Prior GLP-1 failure | Strong evidence base | Mechanistic rationale via glucagon arm | | Insurance coverage | Broad (with PA) | Not commercially available |

Special Populations: CKD and Renal Impairment

Chronic kidney disease affects approximately 37 million Americans and commonly co-occurs with obesity and T2D. [7]

Tirzepatide in CKD

The tirzepatide prescribing information specifies no dose adjustment for any stage of renal impairment, including end-stage renal disease. [1] A pharmacokinetic sub-study nested within SURPASS-4 (N=2,002, adults with T2D and high cardiovascular risk) showed tirzepatide exposure was similar across estimated glomerular filtration rate (eGFR) categories from 15 to 90 mL/min/1.73m2. The SURPASS-4 population itself included a high proportion of patients with CKD stage 3 (eGFR 30 to 59), and no safety signal specific to renal disease was identified. [8]

Tirzepatide may also independently benefit kidney function through weight reduction and blood-pressure lowering. The SELECT trial for semaglutide (a GLP-1-only agonist) showed reduced kidney disease progression, and mechanistically similar benefits are plausible for tirzepatide, though CKD-specific outcome data for tirzepatide await a dedicated trial.

Retatrutide in CKD

No published renal sub-group analyses exist for retatrutide as of mid-2025. The glucagon component introduces a theoretical concern: glucagon can increase renal blood flow and glomerular filtration acutely in some models. Whether this is clinically relevant at the doses used in humans is unknown. The TRIUMPH program's protocols include patients with moderate renal impairment, and those data will be the first real signal.

Patients with stage 4 or 5 CKD should not receive retatrutide outside a monitored trial setting until dedicated renal safety data are published.

Special Populations: Cardiovascular Disease

Cardiovascular disease is the leading cause of death in people with T2D, and outcomes data drive formulary decisions as much as efficacy data do.

Tirzepatide's Cardiovascular Evidence

SURPASS-CVOT, the dedicated cardiovascular outcomes trial for tirzepatide in T2D with high CV risk (target N approximately 13,000), has completed enrollment. Interim results are expected in 2025 to 2026. The trial's primary endpoint is MACE-3 (cardiovascular death, non-fatal MI, non-fatal stroke). [9]

While definitive CVOT data are pending, SURPASS-4 showed tirzepatide was non-inferior to insulin glargine on MACE at 2.5 years in a high-CV-risk T2D cohort, with a hazard ratio point estimate of 0.74 (95% CI 0.51 to 1.08), which, while underpowered for superiority, is directionally consistent with the cardiovascular benefit seen with the GLP-1 class. [8]

The American Diabetes Association's 2024 Standards of Care state: "For patients with type 2 diabetes and established cardiovascular disease, a GLP-1 receptor agonist with proven cardiovascular benefit is recommended." [10] Tirzepatide does not yet carry that label, but liraglutide (LEADER), semaglutide (SUSTAIN-6, SELECT), and dulaglutide (REWIND) all set the precedent.

Retatrutide's Cardiovascular Outlook

No dedicated cardiovascular outcomes data exist for retatrutide. The glucagon receptor component adds complexity: glucagon raises heart rate and can increase myocardial oxygen demand. In the phase 2 trial, retatrutide 12 mg increased mean heart rate by approximately 7 beats per minute, similar to GLP-1 agonist class effects. [2] Whether the glucagon-driven heart-rate increase is clinically adverse at these doses is a key question for the TRIUMPH CVOT, which has not yet been announced.

Patients with recent acute coronary syndrome (<60 days) or decompensated heart failure should only receive retatrutide within a monitored research protocol.

Special Populations: Older Adults (Age 65 and Above)

Tirzepatide in Older Adults

Age-related muscle loss (sarcopenia) and fall risk complicate aggressive weight reduction in adults aged 65 and older. The SURMOUNT-1 sub-group analysis for participants aged 65 and above (approximately 18% of the trial) showed similar percentage weight loss to younger participants but a higher rate of lean-mass reduction relative to total weight loss. [3]

The Endocrine Society's 2023 clinical practice guideline on obesity in older adults notes that any weight-loss pharmacotherapy should be paired with resistance exercise and adequate protein intake (1.0 to 1.2 g/kg/day) to preserve skeletal muscle mass. [11]

Retatrutide in Older Adults

The glucagon component of retatrutide may amplify lean-mass reduction through increased fatty-acid mobilization and potential gluconeogenic effects, though this has not been measured systematically in the phase 2 data. Until phase 3 body-composition sub-studies are published, providers should treat older adults with retatrutide only in trial settings where DEXA body-composition monitoring is built into the protocol.

Special Populations: Women with PCOS and Reproductive Health

Polycystic ovary syndrome (PCOS) affects 8 to 13% of women of reproductive age and frequently co-occurs with insulin resistance and obesity. [12]

Tirzepatide in PCOS

No dedicated PCOS trial for tirzepatide has reported results as of mid-2025. Mechanistically, tirzepatide's GIP and GLP-1 agonism reduces hyperinsulinemia, which is a central driver of androgen excess in PCOS. Case series and retrospective registry data suggest tirzepatide produces menstrual cycle regularization in many patients within 12 to 24 weeks of treatment, mirroring findings with semaglutide in PCOS. [13]

Women using Mounjaro or Zepbound should be counseled that improved fertility may follow weight normalization and insulin sensitization. Adequate contraception is necessary during treatment, and the drug must be discontinued at least 1 to 2 months before planned conception given the absence of teratogenicity data.

Retatrutide in PCOS

No PCOS-specific data exist for retatrutide. The glucagon component has no established interaction with androgen biosynthesis. TRIUMPH programs may include women with PCOS in their metabolic-syndrome sub-groups, but results are years away.

Switching from Mounjaro to Retatrutide: What Clinicians Need to Know

Patients frequently ask whether they can transition from tirzepatide to retatrutide, especially those who plateau on 15 mg tirzepatide and want access to the additional weight loss suggested by retatrutide phase 2 data.

Is Switching Currently Possible?

In 2025, switching is only possible by enrolling in a TRIUMPH phase 3 trial that permits prior GLP-1 or GIP agonist use. Most TRIUMPH protocols allow prior GLP-1 therapy as long as participants have been off it for 90 days before randomization. Patients currently on Mounjaro would need a 3-month washout period before they could be screened. That washout carries a risk of weight regain, which the SURMOUNT-5 extension data suggest can be substantial (mean 14% weight regain within 12 months of tirzepatide discontinuation compared to continued therapy). [3]

No Established Switching Protocol Exists

There is no published pharmacokinetic overlap study, dose-conversion table, or titration bridge between tirzepatide and retatrutide. Assuming that a patient on 15 mg tirzepatide can start retatrutide 12 mg without retitration is not supported by any trial data. The mechanistic addition of a glucagon receptor arm means the tolerability profile may differ, and standard practice would likely require starting retatrutide at the lowest study dose (1 mg in the phase 2 approach) with full titration.

What to Do While Waiting for Retatrutide Approval

Patients who have plateaued on 15 mg tirzepatide have several evidence-based options:

• Confirm injection technique and storage; degraded drug is a common unrecognized cause of plateau
• Optimize dietary protein to 1.2 to 1.6 g/kg/day to preserve lean mass and support satiety
• Add resistance training 3 days per week; SURMOUNT participants who exercised lost more fat mass at the same dose level
• Ask about TRIUMPH trial eligibility at ClinicalTrials.gov (NCT05929651 and related protocols)
• Consider adding metformin (1,500 to 2,000 mg/day) if not already prescribed, as metformin's AMPK activation is mechanistically additive to GLP-1 class agents and costs under $10/month

Dosing, Titration, and Administration Comparison

Tirzepatide Dosing (Approved)

Mounjaro and Zepbound both start at 2.5 mg weekly subcutaneous injection for 4 weeks, then titrate by 2.5 mg every 4 weeks as tolerated to a maximum of 15 mg weekly. The target maintenance dose is the highest tolerated dose, not necessarily the maximum. Most clinical-trial efficacy is concentrated above 10 mg. [1]

Retatrutide Dosing (Phase 2 Protocol)

The Jastreboff 2023 phase 2 used a starting dose of 1 mg weekly with gradual titration over 12 to 24 weeks to target doses of 4 mg, 8 mg, or 12 mg. [2] The titration schedule was slower than tirzepatide's, likely because the glucagon component adds a separate GI tolerability burden. Phase 3 TRIUMPH protocols may use a modified schedule; published protocol documents from clinicaltrials.gov list the planned dosing but final schedules await results.

Safety and Tolerability Comparison

Both agents share the GLP-1 class adverse-event profile: nausea, vomiting, diarrhea, constipation, and reduced appetite. The key differences worth noting clinically are the following.

Nausea and Vomiting

In SURPASS-2, nausea occurred in 17.5% of participants on tirzepatide 15 mg versus 18.0% for semaglutide 1 mg. [4] In the Jastreboff phase 2, nausea reached 45% and vomiting 25% in the retatrutide 12 mg arm, which is notably higher. The aggressive titration schedule in that phase 2 may partly explain this, and phase 3 protocols may show improved tolerability with a slower ramp.

Gallbladder Events

Rapid weight loss increases gallstone risk across all GLP-1 class agents. Tirzepatide's SURMOUNT-1 reported cholelithiasis in 1.2% of the tirzepatide group versus 0.4% of placebo. [3] No comparative gallbladder data exist for retatrutide.

Muscle Loss

A key concern with the glucagon component is whether retatrutide accelerates lean-mass loss relative to tirzepatide. The phase 2 data did not report DEXA body-composition outcomes in detail. Phase 3 protocols for TRIUMPH include body-composition sub-studies, and those results will be critical for older patients and people with low baseline muscle mass.